Ovaban®/Megace® Pills

Active Ingredient
Megestrol acetate

Product Type
Progestin

Manufacturer
Megace®: Bristol-Myers Squibb; Ovaban®: Schering-Plough

Product information
Available as generic megestrol acetate and as Ovaban (approved for domestic dogs) and Megace (approved for treatment of estrogen-sensitive tumors and anorexia in humans), this product can be used for short-term contraception, especially in carnivores and also to suppress the initial stimulation phase (flare) following insertion of the GnRH agonist implant Suprelorin.

Safety to humans
There is no health risk to humans when administered as directed.

Dosing
For use of Ovaban or generic megestrol acetate for suppression of initial estrus/ovulation caused by Suprelorin, the domestic dog dose of 2mg/kg body weight appears to be effective for other species.

Dosage studies have not been conducted for exotic species for use as a contraceptive. While synthetic progestins have been shown to be associated with deleterious effects in carnivores, this product is sometimes suggested for short-term, reliably reversible contraception in carnivores (e.g. no more than 1-2 years). A dose of 0.5-1.0mg/kg is recommended (the higher dose for smaller species and the lower dose for larger ones).

Latency to effectiveness
Although individuals vary, threshold levels of the hormone should be reached in the blood within 1 to 3 days of starting this product. However, pre-ovulatory follicles are difficult to suppress, so, if cycle stage is not known, extra time must be allowed. Therefore, separation or alternative contraception should be used for 1-2 weeks after treatment begins.

Signs of estrus during treatment
Synthetic progestins may achieve contraception by blocking ovulation, causing thickening of cervical mucus, slowing ovum transport, and/or interfering with fertilization or implantation. However, follicle growth may continue and sometimes be accompanied by estrogen production sufficient to cause estrous behavior. Ovulation may occur even though pregnancy does not ensue. Higher progestin doses
may be preferred so that estrous behavior is prevented, but may not be effective in completely suppressing follicle growth and all estrogen production.

**Duration of efficacy and reversibility**
Duration of efficacy may not be much more than 1 day, so the product must be administered daily. Following cessation of treatment, rapid clearance can result in ovulation within a few days, but actual latency to conception will vary by individual.

**Use during pregnancy**
Progestins are not recommended in late pregnancy because of the possibility of prolonged gestation, although the effect may depend on species and dose.

**Use during lactation**
Progestins are sometimes prescribed for lactating women and are considered generally safe for nursing infants.

**Use in pre-pubertal animals**
Lack of data on pre-pubertal treatment and potential long-term effects on fertility contraindicates recommending contraception before puberty. Future reproduction was not affected in calves of domestic cows on MGA-treated feed, but no published studies of pre-pubertal treatment with MGA or other progestins have been conducted with other species, so possible long-term effects on fertility are not known.

**Precautions**
Progestins may cause weight gain in all species. Possible deleterious effects on uterine and mammary tissues vary greatly by species; see cautions for each taxon.

**Consideration for seasonal breeders**
Treatment should begin at least 1 month before the anticipated onset of the breeding season. However, in canids, treatment should begin more than 2 months before the time of anticipated estrus, because proestrus increases in estradiol can begin as much as 2 months before estrus, and it is known that this endogenous estradiol can exacerbate deleterious effects of progestins on the uterus and mammary glands. This synergy of estradiol and progestins may also occur in other carnivores, such as mustelids and ursids.

**Reporting Requirements**
All institutions using this product are asked to contribute contraception information for their animals to the AZA Reproductive Management Center’s Contraception Database ([https://www.zoocontraceptiondata.org](https://www.zoocontraceptiondata.org)). It is essential that accurate records of doses and treatment intervals be maintained, and results reported, to contribute to dosage development.

**For questions about the RMC Contraception Database, contact:**
Ashley Franklin, Program Analyst
AZA Reproductive Management Center
One Government Drive
Saint Louis, MO 63110
301-956-0171; fax: 314-646-5534
franklin@stlzoo.org